New Diagnostic Algorithm Targets Difficult Rheumatoid Arthritis

A framework presented in 2026 aims to better categorize patients who fail standard biologic disease-modifying therapies.

Updated on Oct. 20, 2026 in Arthritis

New Diagnostic Algorithm Targets Difficult Rheumatoid Arthritis

Live Poll

Should patients address non-inflammatory health factors like obesity and sleep when managing chronic arthritis symptoms?

Bryant R. England introduced a diagnostic algorithm at the 2026 Perspectives in Rheumatic Diseases conference to address difficult-to-treat rheumatoid arthritis. This framework distinguishes between symptoms driven by inflammation and those caused by other clinical factors.

Why it matters

The algorithm simplifies management for patients who remain symptomatic despite trying multiple biologic or targeted disease-modifying drugs. By pinpointing whether inflammation or noninflammatory factors are to blame, clinicians can better tailor treatment plans.

Approximately 12% of rheumatoid arthritis cases are classified as difficult-to-treat, though study estimates range from 5% to 25%. Inflammation is estimated to be the primary driver in about 50% of these difficult-to-treat cases.

The players

Bryant R. England

He is a researcher associated with the University of Nebraska Medical Center who developed the diagnostic algorithm for managing difficult-to-treat rheumatoid arthritis.

The details

The algorithm categorizes patients into three distinct phenotypes: chronic pain, multimorbidity, and persistent inflammatory refractory rheumatoid arthritis. It employs three decision points that assess joint involvement, laboratory markers of inflammation, and contributing comorbidities like cardiovascular or respiratory diseases.

2022: EULAR D2T RA recommendations were published.
2025: A review article on D2T RA was published.
2026: The algorithm was outlined at the Perspectives in Rheumatic Diseases conference.

Health Landscape

This algorithm extends the 2022 EULAR D2T RA recommendations by providing an actionable diagnostic framework for clinical use. It builds upon the established clinical definitions of treatment failure to improve precision in medical care.

Patients with persistent rheumatoid arthritis symptoms may benefit from more targeted care strategies that isolate whether their pain is inflammatory or related to other comorbidities. This approach helps reduce ineffective drug trials by clearly identifying the root cause of ongoing symptoms.

The takeaway

Clinicians are increasingly moving toward individualized phenotype categorization rather than uniform treatment approaches for refractory cases. Patients should discuss with their rheumatologist whether their symptoms are primarily inflammatory or driven by comorbid conditions.